Thromboembolic Events Related to Treatment with Checkpoint Inhibitors: Report of Two Cases
Despite the significant clinical benefits, checkpoint inhibition is associated with a unique spectrum of immune-related adverse events. It is sometimes difficult to distinguish some rare adverse effects from a cancer progression; thus, such effects should be reported in clinical trials to be diagnos...
Main Authors: | Jessica Tsukamoto, Mariana Monteiro, Silvana Vale, Cynthia Lemos, Thais Scarpelli, Leticia Carvalho, Daniela Pezzutti, Raphael Brandão |
---|---|
Format: | Article |
Language: | English |
Published: |
Karger Publishers
2018-10-01
|
Series: | Case Reports in Oncology |
Subjects: | |
Online Access: | https://www.karger.com/Article/FullText/492463 |
Similar Items
-
A bispecific anti-PD-1 and PD-L1 antibody induces PD-1 cleavage and provides enhanced anti-tumor activity
by: Diana I. Albu, et al.
Published: (2024-12-01) -
Characterising CD8+ T cell transcriptomic and clonal consequences of immune checkpoint blockade for the treatment of cancer
by: Watson, RA
Published: (2023) -
The Immunotherapy Landscape in Adrenocortical Cancer
by: Guillaume J. Pegna, et al.
Published: (2021-05-01) -
Future prospects for breast cancer immunotherapy
by: V. F. Semiglazov, et al.
Published: (2018-11-01) -
Pulmonary Artery Intimal Sarcoma Involving the Peripheral Pulmonary Artery, Initially Misdiagnosed as Pulmonary Artery Thromboembolism and Vasculitis: A Case Report
by: Min Seong Kim, et al.
Published: (2023-11-01)